Albany, NY -- (SBWIRE) -- 11/26/2018 -- DelveInsight has announced the addition of the "Eosinophilic esophagitis (EoE) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of EOE for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Eosinophilic Esophagitis (EoE) forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Eosinophilic Esophagitis (EoE), often referred to as "asthma of the oesophagus", is a chronic allergic/immune condition, which tends to reflect many similar clinical and pathophysiologic characteristics as with asthma. It is characterized by the inflammation of the oesophagus, and hence, termed as an atopic inflammatory disease of the oesophagus.

EoE is marked by the presence of Eosinophil, a type of white blood cell, which is typically present throughout the lining of the oesophagus (gastrointestinal tract). The production and accumulation of eosinophils may be caused by many factors, such as immune hypersensitivity responses to particular foods or environmental proteins (allergens) in some affected individuals. The symptoms of eosinophilic esophagitis are variable, especially in people of different ages. Common symptoms include difficulty in swallowing (dysphagia); food getting stuck in the throat (impaction); nausea; vomiting; poor growth; weight loss; stomach pain; poor appetite; and malnutrition. The prevalence of EoE is higher among men than women.

The total prevalent population of EoE in the 7 major markets were found to be 433,358 cases in 2016. DelveInsight also estimates the higher prevalence of EoE in the United States with 191,291 in 2016, followed by EU5 and Japan. Among the European countries, Germany had the highest prevalent population of EoE with 50,290 cases, followed by France, which had the prevalent population of 41,639 in 2016. On the other hand, Italy had the lowest prevalent population of 38,631 in 2016. Based on DelveInsight analysis, it has been concluded that approximately 15.90% of total US prevalent population of EoE was the childhood group (i.e., ?18 years of age), accounting for 30,415 cases, while around 84.1% of the total were adults (i.e., >18 years), accounting for 160,876 patients in the year 2016.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Shire
2. Dr. Falk GmBH
3. Adare Pharmaceuticals
4. Regeneron
And many others

Drugs covered
1. EoE- SHP621
2. Jorveza
3. APT-1011
4. Dupilumab
And many others

Report Scope
The report covers a descriptive overview of the Eosinophilic Esophagitis (EoE), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Eosinophilic Esophagitis (EoE) and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Eosinophilic Esophagitis (EoE) are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Eosinophilic Esophagitis (EoE) market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Eosinophilic Esophagitis (EoE) market.